Medani Samar, Dorais Marc, Poulin Aurélie, Tavares-Brum Alexandre, Mawad Habib, Duclos Alain, Barama Azemi, Cardinal Héloïse
Research Centre, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.
Statsciences, Notre-Dame de l'Ile Perrot, QC, Canada.
Kidney Med. 2024 Dec 15;7(2):100946. doi: 10.1016/j.xkme.2024.100946. eCollection 2025 Feb.
RATIONALE & OBJECTIVE: Management of asymptomatic bacteriuria in kidney transplant recipients remains uncertain. Our main objective was to evaluate whether patient- or episode-related factors could help identify episodes of asymptomatic bacteriuria associated with a higher risk of being followed by a symptomatic urinary tract infection.
A single-center, retrospective cohort study.
SETTINGS & PARTICIPANTS: Consecutive patients who received a kidney transplantation between January 1, 2008, and April 26, 2016, and experienced ≥1 episode of asymptomatic bacteriuria during the first 3 years posttransplantation.
Recipient age, sex, diabetes, donor type, retransplant, urological abnormalities, thymoglobulin for induction, time since transplant, presence of ureteral stent, prior acute rejection, leukocyturia, hematuria, urinary nitrites, bacterial strain, prior urinary tract infection, resistance to antibiotics, antibiotic treatment.
The primary outcome was the occurrence of symptomatic urinary tract infection. The secondary outcome was antibiotic treatment of asymptomatic bacteriuria.
A Cox regression survival analysis model accounting for recurrent events and a logistic regression model.
From a cohort of 508 patients, we included 597 episodes of asymptomatic bacteriuria detected in 119 outpatients. Antibiotics were prescribed in 26% of these episodes. Overall, 56 (9%) of episodes were followed by a symptomatic urinary tract infection. Pretransplant diabetes (hazard ratio [HR], 4.28; 95% confidence intervals [CI], 2.40-7.61), leukocyturia or hematuria (HR, 2.24; 95% CI, 1.27-3.96), and the presence of a ureteral stent (HR, 3.40; 95% CI, 1.33-8.70) were associated with development of a clinical urinary tract infection in patients with asymptomatic bacteriuria.
The small number of events limits complete multivariable adjustment. It also prevents us from drawing a definite conclusion about the importance of a number of independent variables as risk factors for the outcome.
The benefit of treating episodes of asymptomatic bacteriuria with high-risk characteristics should be investigated in future trials.
肾移植受者无症状菌尿的管理仍不明确。我们的主要目的是评估患者相关因素或发作相关因素是否有助于识别那些随后发生有症状性尿路感染风险较高的无症状菌尿发作情况。
一项单中心回顾性队列研究。
2008年1月1日至2016年4月26日期间接受肾移植且在移植后前3年经历过≥1次无症状菌尿发作的连续患者。
受者年龄、性别、糖尿病、供体类型、再次移植、泌尿系统异常、诱导期使用抗胸腺细胞球蛋白、移植后的时间、输尿管支架的存在、既往急性排斥反应、白细胞尿、血尿、尿亚硝酸盐、细菌菌株、既往尿路感染、抗生素耐药性、抗生素治疗。
主要结局是有症状性尿路感染的发生。次要结局是无症状菌尿的抗生素治疗。
采用考虑复发事件的Cox回归生存分析模型和逻辑回归模型。
在508例患者队列中,我们纳入了119例门诊患者中检测到的597次无症状菌尿发作情况。其中26%的发作情况使用了抗生素。总体而言,56次(9%)发作后发生了有症状性尿路感染。移植前糖尿病(风险比[HR],4.28;95%置信区间[CI],2.40 - 7.61)、白细胞尿或血尿(HR,2.24;95%CI,1.27 - 3.96)以及输尿管支架的存在(HR,3.40;95%CI,1.33 - 8.70)与无症状菌尿患者发生临床尿路感染相关。
事件数量较少限制了完全多变量调整。这也使我们无法就一些独立变量作为结局危险因素的重要性得出明确结论。
未来试验应研究治疗具有高危特征的无症状菌尿发作的益处。